Citius Pharmaceuticals, Inc.

Name: Citius Pharmaceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

CTXRNasdaqCIK 1506251HealthcareFiscal year ends Sep 30

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.5m, Q3 FY2026

Operating income−$11.7m, Q3 FY2026

Net income−$11.9m, Q3 FY2026

Citius Pharmaceuticals, Inc., income statement, quarterly
Line item	Unit	Q4 FY20232023-09-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	Q4 FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q4 FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	3.9	1.7	1.5
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.8	0.3	0.5
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	3.2	1.3	1.0
Research and development	$m	2.9	2.6	3.6	2.8	2.9	2.1	3.8	1.6	1.6	1.6	1.6	1.1
Operating income	$m	(10.1)	(9.3)	(11.0)	(10.6)	(11.1)	(10.0)	(11.3)	(8.8)	(8.4)	(9.0)	(32.2)	(11.7)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.2	0.1	0.2	0.0	0.2
Income tax	$m	0.1	0.1	0.1	0.1	0.1	0.3	0.3	0.3	0.3	0.3	(0.2)	(0.1)
Net income	$m	(9.9)	9.2	(8.5)	(10.6)	(11.1)	(10.3)	(11.5)	(9.2)	(8.7)	(9.4)	(28.1)	(11.9)
Diluted EPS	$ per share	not reported	(1.45)	(1.34)	(1.57)	not reported	(1.30)	(1.27)	(0.80)	not reported	(0.38)	(0.95)	(0.34)
Basic EPS	$ per share	not reported	(1.45)	(1.34)	(1.57)	not reported	(1.30)	(1.27)	(0.80)	not reported	(0.38)	(0.95)	(0.34)

Balance sheet

Cash and equivalents$17.0m, Q3 FY2026

Shareholders' equity$66.6m, Q3 FY2026

Citius Pharmaceuticals, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-09-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Cash and equivalents	$m	26.5	20.3	12.6	17.9	3.3	1.1	0.0	6.1	4.3	7.7	4.6	17.0
Current assets	$m	34.4	28.2	21.6	28.0	14.2	18.3	18.4	24.6	27.9	37.9	31.7	43.3
Total assets	$m	104	97.4	90.7	97.1	117	121	121	128	131	140	133	142
Current liabilities	$m	5.8	5.6	4.2	4.2	35.8	44.8	49.9	51.8	44.9	38.2	55.0	51.6
Total liabilities	$m	12.2	12.1	10.7	10.8	42.5	51.8	57.9	60.1	53.4	46.9	63.5	66.3
Short-term borrowings	$m	not reported	not reported	not reported	not reported	not reported	300	300	300	300	300	300	300
Shareholders' equity	$m	90.8	84.7	79.4	85.7	70.1	65.4	60.7	65.1	67.6	80.0	61.5	66.6

Cash flow

Operating cash flow−$8.7m, Q3 FY2026

Citius Pharmaceuticals, Inc., cash flow, quarterly
Line item	Unit	Q4 FY20232023-09-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	Q4 FY20242024-09-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q4 FY20252025-09-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Operating cash flow	$m	(6.8)	(6.1)	(7.8)	(8.4)	(5.9)	(4.7)	(4.5)	(5.4)	(11.9)	(13.0)	(1.3)	(8.7)
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)26.17m, Q3 FY2026

Citius Pharmaceuticals, Inc., shares, quarterly
Line item	Unit	Q1 FY20232022-12-31	Q2 FY20232023-03-31	Q3 FY20232023-06-30	Q1 FY20242023-12-31	Q2 FY20242024-03-31	Q3 FY20242024-06-30	Q1 FY20252024-12-31	Q2 FY20252025-03-31	Q3 FY20252025-06-30	Q1 FY20262025-12-31	Q2 FY20262026-03-31	Q3 FY20262026-06-30
Diluted shares (weighted)	m shares	146	146	154	6.4	6.4	7.0	7.5	8.6	11.0	21.5	22.4	26.2

Shares outstanding: 27.45m at Aug 13, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. Listed shows no prices and gives no investment advice.